Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration

被引：0
|
作者：
Byung-Jin Ahn
Moon Ki Choi
Young Suk Park
Jeeyun Lee
Se Hoon Park
Joon Oh Park
Ho Yeong Lim
Won Ki Kang
Jae-Wook Ko
Dong-Seok Yim
机构：
[1] Dongguk University,Medical Science Research Center
[2] Sungkyunkwan University School of Medicine,Division of Hematology
[3] Samsung Medical Center,Oncology, Department of Medicine, Samsung Medical Center
[4] The Catholic University of Korea,Department of Clinical Pharmacology & Therapeutics
来源：
European Journal of Clinical Pharmacology | 2010年 / 66卷
关键词：
Gastric cancer; CPT-11; Intraperitoneal administration; Pharmacokinetics; NONMEM;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1235 / 1245
页数：10
相关论文
共 50 条
  • [21] Combination therapy with S-1 and irinotecan (CPT-11) for advanced or recurrent gastric cancer
    Takiuchi, Hiroya
    GASTRIC CANCER, 2009, 12 : 55 - 59
  • [22] Combination therapy with S-1 and irinotecan (CPT-11) for advanced or recurrent gastric cancer
    Hiroya Takiuchi
    Gastric Cancer, 2009, 12 : 55 - 59
  • [23] Irinotecan (CPT-11) as first line treatment of patients with not pretreated advanced colorectal cancer
    Firyida, JL
    Menendez, MD
    Mel, JR
    Diz, P
    Constenla-Figueiras, M
    Casal, J
    Valladares, M
    Castellanos, J
    Balcells, M
    ANNALS OF ONCOLOGY, 1998, 9 : 38 - 39
  • [24] CPT-11 is an active agent in patients with advanced gastric cancer.
    Köhne, CH
    Catane, R
    Klein, H
    Peretz, T
    Preusser, P
    Niederle, N
    Ducreux, M
    Wilke, H
    Jacques, C
    CLINICAL CANCER RESEARCH, 1999, 5 : 3773S - 3773S
  • [25] A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer
    Heather Wakelee
    George A. Fisher
    Investigational New Drugs, 2005, 23 : 241 - 242
  • [26] A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer
    Wakelee, H
    Fisher, GA
    INVESTIGATIONAL NEW DRUGS, 2005, 23 (03) : 241 - 242
  • [27] Combination of irinotecan (CPT-11) and nedaplatin (NDP) for recurrent patients with uterine cervical cancer
    Tatsuru Ohara
    Yoichi Kobayashi
    Ayako Yoshida
    Norihito Yoshioka
    Namiko Yahagi
    Haruhiro Kondo
    Akiko Tozawa
    Kazushige Kiguchi
    Nao Suzuki
    International Journal of Clinical Oncology, 2013, 18 : 1102 - 1106
  • [28] Combination of irinotecan (CPT-11) and nedaplatin (NDP) for recurrent patients with uterine cervical cancer
    Ohara, Tatsuru
    Kobayashi, Yoichi
    Yoshida, Ayako
    Yoshioka, Norihito
    Yahagi, Namiko
    Kondo, Haruhiro
    Tozawa, Akiko
    Kiguchi, Kazushige
    Suzuki, Nao
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (06) : 1102 - 1106
  • [29] Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients
    Spinel Karas
    Amy S. Etheridge
    Eleftheria Tsakalozou
    Jacqueline Ramírez
    Erika Cecchin
    Ron H.N. van Schaik
    Giuseppe Toffoli
    Mark J. Ratain
    Ron H.J. Mathijssen
    Alan Forrest
    Robert R. Bies
    Federico Innocenti
    The AAPS Journal, 22
  • [30] Phase I study of irinotecan (CPT-11) combined with S-1 in patients with advanced gastric cancer(AGC)
    Komatsu, Y
    Takei, M
    Kato, T
    Miyagishima, T
    Kunieda, Y
    Tateyama, M
    Wakahama, O
    Takeda, H
    Kato, M
    Sugiyama, T
    Asaka, M
    Sakata, Y
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 253 - 254
12345